In a recent article with Life Sciences Knowledge Hub, Quotient Sciences executives speak to industry trends including artificial intelligence (Ai)
Thierry Van Nieuwenhove and Kieron Hall, Chief Marketing Officer, share insight about the role of artificial intelligence (Ai) and its impact to contract pharmaceutical manufacturing.
“I think AI is a revolution for the industry,” says Thierry Van Nieuwenhove, CEO of Quotient Sciences, “This is really what’s going to change the industry substantially. And the whole industry is still looking at how this could actually accumulate, being implemented into the shop and into the value chain of developing a drug but also later on of adding a drug on the market.”
Read the full article, "Looking Back at DCAT Week 2024," on the Life Sciences Knowledge Hub website.